Technical Analysis for ITCI - Intra-Cellular Therapies Inc.

Grade Last Price % Change Price Change
D 65.37 0.91% 0.59
ITCI closed up 0.91 percent on Monday, March 18, 2024, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Flat

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup 0.91%
Narrow Range Bar Range Contraction 0.91%
Inside Day Range Contraction 0.91%
Oversold Stochastic Weakness 0.91%
Hammer Candlestick Bullish 1.24%
Oversold Stochastic Weakness 1.24%
Bullish Engulfing Bullish 0.25%
Stochastic Reached Oversold Weakness 0.25%
Outside Day Range Expansion 0.25%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 15 hours ago
Rose Above 10 DMA about 15 hours ago
Rose Above Previous Day's High about 17 hours ago
10 DMA Resistance about 17 hours ago
Up 1% about 17 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Intra-Cellular Therapies Inc. Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical IBD 50 Neuroscience Alzheimer's Disease Disorders Parkinson's Disease Drug Development Mental Health Schizophrenia Dysfunction Dementia Major Depressive Disorder Psychiatric Diagnosis Psychiatry Human Diseases Depressive Disorder Neurodegeneration Treatment Of Parkinson's Disease Aging Associated Diseases Autism Spectrum Disorder Bipolar Disorder Hyperactivity Disorder Insomnia Cognitive Disorders Psychiatric Disorders Cognitive Impairment Autism Learning Disabilities Phosphodiesterase Cardiovascular And Other Diseases Cognitive Dysfunction Ptsd Treatment Of Human Diseases

Is ITCI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 76.11
52 Week Low 44.9
Average Volume 800,776
200-Day Moving Average 61.42
50-Day Moving Average 68.79
20-Day Moving Average 68.47
10-Day Moving Average 65.66
Average True Range 2.39
RSI (14) 42.20
ADX 28.76
+DI 18.02
-DI 30.49
Chandelier Exit (Long, 3 ATRs) 68.94
Chandelier Exit (Short, 3 ATRs) 69.95
Upper Bollinger Bands 74.83
Lower Bollinger Band 62.12
Percent B (%b) 0.26
BandWidth 18.56
MACD Line -1.41
MACD Signal Line -0.91
MACD Histogram -0.4997
Fundamentals Value
Market Cap 6.29 Billion
Num Shares 96.2 Million
EPS -1.62
Price-to-Earnings (P/E) Ratio -40.35
Price-to-Sales 16.67
Price-to-Book 11.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 67.22
Resistance 3 (R3) 67.21 66.60 66.91
Resistance 2 (R2) 66.60 66.13 66.60 66.80
Resistance 1 (R1) 65.98 65.84 66.29 65.99 66.70
Pivot Point 65.37 65.37 65.52 65.37 65.37
Support 1 (S1) 64.75 64.90 65.06 64.76 64.04
Support 2 (S2) 64.14 64.61 64.14 63.94
Support 3 (S3) 63.52 64.14 63.83
Support 4 (S4) 63.53